A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glaltiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting multiple Sclerosis (CombiRx-PhaseIII)

Grant

Awarded By

Total Award Amount

  • 399922.00

    • Direct Costs

  • 276762.00

    • Sponsor Award Id

    • Contributor

  • Khurram Bashir   Principal Investigator